Summary:
12 visits over 1.5 years.
Study is to test the safety and efficacy of Semaglutide and the fixed-dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Qualified Participants Must:
• Be between 18-80 years old
•
Have a BMI of 23 or more
•
Have no other liver disorders
Qualified Participants May Receive:
Up to $1450 if all visits and procedures are completed